{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:36:51Z","timestamp":1791398211438,"version":"4.3.3"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Centers for Disease Control and Prevention. We identified 21 patients on recent rituximab therapy who were diagnosed with an arboviral disease caused by West Nile, tick-borne encephalitis, eastern equine encephalitis, Cache Valley, Jamestown Canyon, and Powassan viruses. All reported patients had neuroinvasive disease. The diagnosis of arboviral infection required molecular testing in 20 (95%) patients. Median illness duration was 36 days (range, 12 days to 1 year), and 15\/19 (79%) patients died from their illness. Patients on rituximab with arboviral disease can have a severe or prolonged course with an absence of serologic response. Patients should be counseled about mosquito and tick bite prevention when receiving rituximab and other B-cell depleting therapies.<\/jats:p>","DOI":"10.1093\/cid\/ciac766","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T05:08:11Z","timestamp":1663132091000},"page":"1142-1148","source":"Crossref","is-referenced-by-count":42,"title":["Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review"],"prefix":"10.1093","volume":"76","author":[{"given":"Ronak K","family":"Kapadia","sequence":"first","affiliation":[{"name":"Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine , Aurora, Colorado , USA"},{"name":"Division of Neurology, Department of Clinical Neurosciences, Cummings School of Medicine, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Erin","family":"Staples","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Gill","sequence":"additional","affiliation":[{"name":"University of Iowa, Carver College of Medicine, Department of Neurology , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezza","family":"Khan","sequence":"additional","affiliation":[{"name":"Hunterdon Infectious Disease Specialists , Flemington, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janeen J","family":"Laven","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Panella","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason O","family":"Velez","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly R","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Brault","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Pastula","sequence":"additional","affiliation":[{"name":"Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine , Aurora, Colorado , USA"},{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"},{"name":"Department of Epidemiology, Colorado School of Public Health , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn V","family":"Gould","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3201\/eid2701.203448","article-title":"Fatal case of chronic Jamestown Canyon virus encephalitis diagnosed by metagenomic sequencing in patient receiving rituximab","volume":"27","author":"Solomon","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"D\u00f6rner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"2023032201030271200_","author":"Food and Drug Administration"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract Neurol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"e00558","DOI":"10.1016\/j.idcr.2019.e00558","article-title":"Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: a case report and brief literature review","volume":"17","author":"Tellez","year":"2019","journal-title":"IDCases"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"577639","DOI":"10.1016\/j.jneuroim.2021.577639","article-title":"Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab","volume":"358","author":"Kapadia","year":"2021","journal-title":"J Neuroimmunol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7001a1","article-title":"Surveillance for West Nile virus disease\u2014United States, 2009\u20132018","volume":"70","author":"McDonald","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"2023032201030271200_","first-page":"133","volume-title":"Neurological complications of infectious diseases","author":"Gould","year":"2021"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"496","DOI":"10.15585\/mmwr.mm6717e1","article-title":"Vital Signs: trends in reported vectorborne disease cases\u2014United States and territories, 2004\u20132016","volume":"67","author":"Rosenberg","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023032201030271200_","first-page":"287","article-title":"Neuroinvasive West Nile virus disease in an elderly patient with diffuse large B-cell lymphoma treated with R-CHOP therapy: a case report","volume":"36","author":"Arslan","year":"2019","journal-title":"Balkan Med J"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.amjmed.2017.01.014","article-title":"Seronegative West Nile virus infection in a patient treated with rituximab for rheumatoid arthritis","volume":"130","author":"Goates","year":"2017","journal-title":"Am J Med"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/1756-0500-7-852","article-title":"Delayed-onset flaccid paralysis related to West Nile virus reactivation following treatment with rituximab: a case report","volume":"7","author":"Honig","year":"2014","journal-title":"BMC Research Notes"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3201\/eid0812.020532","article-title":"First isolation of West Nile virus from a patient with encephalitis in the United States","volume":"8","author":"Huang","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2023032201030271200_","first-page":"855","article-title":"Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab","volume":"56","author":"Knight","year":"2017","journal-title":"Rheumatol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1399-0012.2009.01044.x","article-title":"Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients","volume":"24","author":"Levi","year":"2010","journal-title":"Clin Transplant"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLM.2005.n.053","article-title":"Fatal West Nile virus infection after rituximab\/fludarabine\u2013induced remission for non-Hodgkin's lymphoma","volume":"6","author":"Mawhorter","year":"2005","journal-title":"Clinical Lymphoma & Myeloma"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"ofv136","DOI":"10.1093\/ofid\/ofv136","article-title":"West Nile virus central nervous system infection in patients treated with rituximab: implications for diagnosis and prognosis, with a review of literature","volume":"2","author":"Morjaria","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s13365-020-00854-z","article-title":"West Nile virus neuroinvasive disease associated with rituximab therapy","volume":"26","author":"Owens","year":"2020","journal-title":"J Neurovirol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"ofx021","DOI":"10.1093\/ofid\/ofx021","article-title":"Fatal eastern equine encephalitis in a patient on maintenance rituximab: a case report","volume":"4","author":"Solomon","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2018.0132","article-title":"Fatal Powassan encephalitis (deer tick virus, lineage II) in a patient with fever and orchitis receiving rituximab","volume":"75","author":"Solomon","year":"2018","journal-title":"JAMA Neurol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"ofx204","DOI":"10.1093\/ofid\/ofx204","article-title":"Two cases of severe tick-borne encephalitis in rituximab-treated patients in Germany: implications for diagnosis and prevention","volume":"4","author":"Steininger","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1097\/HS9.0000000000000395","article-title":"Clinical characteristics and outcome of West Nile virus infection in patients with lymphoid neoplasms: an Italian multicentre study","volume":"4","author":"Visentin","year":"2020","journal-title":"HemaSphere"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5694\/mja2.50416","article-title":"Diagnosis of West Nile virus encephalitis in a returned traveller","volume":"211","author":"Whyler","year":"2019","journal-title":"Med J Aust"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ajh.25024","article-title":"Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy","volume":"93","author":"Yang","year":"2018","journal-title":"Am J Hematol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3201\/eid2707.210315","article-title":"Fatal human infection with evidence of intrahost variation of eastern equine encephalitis virus, Alabama, USA, 2019","volume":"27","author":"Hughes","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.2012.12-0113","article-title":"Medical risk factors for severe West Nile virus disease, United States, 2008\u20132010","volume":"87","author":"Lindsey","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/JVI.77.4.2578-2586.2003","article-title":"B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus","volume":"77","author":"Diamond","year":"2003","journal-title":"J Virol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jama.290.4.511","article-title":"Neurologic manifestations and outcome of West Nile virus infection","volume":"290","author":"Sejvar","year":"2003","journal-title":"JAMA"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm7032a1","article-title":"West Nile virus and other domestic nationally notifiable arboviral diseases\u2014United States, 2019","volume":"70","author":"Vahey","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMcpc059017","article-title":"Case records of the Massachusetts General Hospital. Case 22-2005. An 81-year-old man with cough, fever, and altered mental status","volume":"353","author":"Hollander","year":"2005","journal-title":"N Engl J Med"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4269\/ajtmh.15-0196","article-title":"Jamestown Canyon virus disease in the United States\u20142000\u20132013","volume":"93","author":"Pastula","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QCO.0000000000000729","article-title":"Arboviral central nervous system infections","volume":"34","author":"Schultz","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/591467","article-title":"Virus and antibody dynamics in acute West Nile virus infection","volume":"198","author":"Busch","year":"2008","journal-title":"J Infect Dis"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1212\/01.wnl.0000195890.70898.1f","article-title":"CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis","volume":"66","author":"Tyler","year":"2006","journal-title":"Neurol"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJM199706263362604","article-title":"Clinical and neuroradiographic manifestations of eastern equine encephalitis","volume":"336","author":"Deresiewicz","year":"1997","journal-title":"N Engl J Med"},{"key":"2023032201030271200_","author":"Centers for Disease Control and Prevention"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","article-title":"Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data","volume":"54","author":"Danese","year":"2016","journal-title":"Med Care"},{"key":"2023032201030271200_","first-page":"832","article-title":"Indications for rituximab use in an integrated health care delivery system","volume":"26","author":"Delate","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2023032201030271200_","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1097\/HS9.0000000000000515","article-title":"Introduction of biosimilar rituximab: a hospital perspective","volume":"5","author":"Cheesman","year":"2021","journal-title":"Hemasphere"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac766\/46394484\/ciac766.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/6\/1142\/49587557\/ciac766.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/6\/1142\/49587557\/ciac766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T22:47:24Z","timestamp":1701038844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/6\/1142\/6698570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,9,14]]},"published-print":{"date-parts":[[2023,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac766","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,15]]},"published":{"date-parts":[[2022,9,14]]}}}